This Predoctoral Training Program is designed to provide a broad education in the Pharmacological Sciences leading to the Ph.D. degree. The Pharmacological Sciences Training Program (PSTP) is based primary in the Department of Pharmacology at the University of Pittsburgh School of Medicine, but includes faculty from four schools within the University and sixteen departments including Anesthesiology, Cell Biology and Physiology, Chemistry, Environmental and Occupational Health, Neurobiology and Pharmaceutical Sciences. Graduate students entering this program are first recruited into the Interdisciplinary Biomedical Graduate Program where they start a program that includes core didactic education and research rotations. Students then transfer into the specialized PhD program of their choice and become candidates for support by the PSTP in their second year. The training program provides graduate classes in the essential elements of modern pharmacology, including neuropharmacology, cancer pharmacology, cardiovascular pharmacology, signal transduction and drug discovery, and also the elements of quantitative pharmacokinetics, pharmacodynamics and drug metabolism. Students choose mentors from a well-funded faculty in one of four research areas: Cancer Pharmacology, Signal Transduction, Drug Discovery or Cell and Organ System Pharmacology. Following completion of the comprehensive exam and a dissertation proposal, students are engaged full time in research in the third and subsequent years of this program. The PSTP also emphasizes training in the responsible conduct of research and provides training in skills that promote professional development. The PSTP thus provides a contemporary and exciting training opportunity for motivated students within a rich research environment, and aims to generate Ph.D. graduates with a broad understanding of the discipline of pharmacology. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008424-12
Application #
7083741
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Preusch, Peter C
Project Start
1994-07-01
Project End
2010-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
12
Fiscal Year
2006
Total Cost
$122,588
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Brady, Megan L; Pilli, Jyotsna; Lorenz-Guertin, Joshua M et al. (2018) Depolarizing, inhibitory GABA type A receptor activity regulates GABAergic synapse plasticity via ERK and BDNF signaling. Neuropharmacology 128:324-339
Basudan, Ahmed; Priedigkeit, Nolan; Hartmaier, Ryan J et al. (2018) Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Mol Cancer Res :
Ye, Jing; Das, Sabyasachi; Roy, Adhiraj et al. (2018) Ischemic Injury-Induced CaMKII? and CaMKII? Confer Neuroprotection Through the NF-?B Signaling Pathway. Mol Neurobiol :
Weir, Mark C; Shu, Sherry T; Patel, Ravi K et al. (2018) Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chem Biol 13:1551-1559
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Zhang, Xuefeng; Cao, Shufen; Barila, Guillermo et al. (2018) Correction: Cyclase-associated protein 1 (CAP1) is a prenyl-binding partner of Rap1 GTPase. J Biol Chem 293:13849
Lorenz-Guertin, Joshua M; Bambino, Matthew J; Jacob, Tija C (2018) ?2 GABAAR Trafficking and the Consequences of Human Genetic Variation. Front Cell Neurosci 12:265
Nagle, Alison M; Levine, Kevin M; Tasdemir, Nilgun et al. (2018) Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res 24:5165-5177
Hartmaier, R J; Trabucco, S E; Priedigkeit, N et al. (2018) Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol 29:872-880
Meijles, Daniel N; Sahoo, Sanghamitra; Al Ghouleh, Imad et al. (2017) The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1. Sci Signal 10:

Showing the most recent 10 out of 63 publications